Skip to main content

View full-text article in PMC

. 2006 Jun 13;108(7):2332–2338. doi: 10.1182/blood-2006-02-004580

Table 2.

Cellular proliferation IC₅₀ values of BCR-ABL point mutants recovered in the presence of nilotinib and dasatinib

	Nilotinib		Dasatinib		Imatinib mesylate
Mutation	IC₅₀, nM	Fold change	IC₅₀, nM	Fold change	IC₅₀, nM	Fold change
L248V	NR^*	NR^*	NR	NR	NR	NR
G250E	48^*	4^*	1.8	2	1350	5
Q252H	70	4	3.4^†	2^†	1325	5
Y253H	450^†	35^†	1.3	2	> 6400	> 25
E255K	200^*	14^*	5.6	7	5200	20
E255V	430^†	33^†	11	14	> 6400	> 25
E292V	NR^*	NR^*	NR	NR	NR	NR
V299L	NR	NR	18^*	13.4^*	540	1.7
T3151	> 2000^‡	> 154^‡	> 200^‡	> 250^‡	> 6400	> 25
F317C	NR	NR	NR^*	NR^*	1200	3
F317L	50	4	7.4^*	9^*	1050	4
F3171	NR	NR	NR^*	NR^*	NR	NR
F317V	350	1.1	53^†	40^†	500	1.3
F359C	NR	NR	NR^*	NR^*	1200	3

Imatinib mesylate values are provided for comparison.

NR indicates not reported.

^*

Mutants recovered at lower drug concentrations.

^†

Mutations recovered at intermediate drug concentrations.

^‡

Mutations recovered at high drug concentrations.¹⁸,²¹,²⁸